MoonLake Immunotherapeutics
sonelokimab (SLK)
hidradenitis suppurativa (HS)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews sonelokimab (SLK) for hidradenitis suppurativa (HS) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“On May 10, 2026, the Company issued a press release announcing the positive outcome from its final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (the “FDA”), where the Company and the FDA aligned”